DRAFT RESOLUTION 1.2COUNCIL : World Health Organization (WHO)SPONSORS : Brazil, Germany, Japan, Myanmar, United States of America, Viet Nam

The World Health Organization,

Alarmed that tuberculosis has infected 8.6 million people all across the globe annually and is considered as a disease with second highest mortality rate after HIV/AIDS;

Deeply concerned that access to proper and standardized treatments and health services remain inaccessible to more than 3 million people across the globe;

Recognizing the need for joint programme between WHO and diverse UN body, limited but not limited to UN Women, UNICEF, WFP, UNAIDS, UNDP, UNHRC and UNHCR to significantly expand and strengthen its work on global, regional and national level in combating tuberculosis;

Recognizing the many factors contributing to the spread and transmission of tuberculosis, including but not limited to weakened immune system due to malnutrition and other diseases such as HIV/AIDS;

Recognizing the different needs and problems faced by vulnerable groups, including women, children, persons with HIV/AIDS, internally displaced people and refugees, and persons living below the poverty line in receiving accessible tuberculosis treatments and other related health services;

Recalling the General Assembly’s resolution A/RES/58/179 on “Access to medication in the context of pandemics such as HIV/AIDS, tuberculosis, and malaria”;

Recalling its resolution WHA44.8 on “Tuberculosis control programme”, resolution WHA53.1 on “Stop Tuberculosis Initiative”, resolution WHA58.14 on “Sustainable financing for tuberculosis prevention and control”, resolution WHA60.19 on “Tuberculosis control: progress and long-term planning”, and resolution WHA62.15 on “Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis”;

Taking into account the Commission on Narcotic Drugs’ resolution 53/4 on “Promoting adequate availability of internationally controlled licit drugs for medical and scientific purposes while preventing their diversion and abuse” and resolution 54/6 on “Promoting adequate availability of internationally controlled narcotic drugs and psychotropic substances for medical and scientific purposes while preventing their diversion and abuse”;

Having considered the WHA62/15 report on “The prevention and control of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis;

Urges all Member States:1) To achieve greater accessibility of health services and information related to the promotion,

prevention, treatment, care and recovery of tuberculosis by means of:a. Establishing more accessible testing centers to increase the availability of standardized

early diagnosis in order to reduce mortality rate caused by tuberculosis; b. Increasing the number and distribution of health care service centers, including clinics

hospitals, with a priority for vulnerable groups including but not limited to women,

children, persons with HIV/AIDS, persons living below national and/or global poverty line, and persons living in inaccessible areas;

c. Making available sufficiently trained and motivated staffs in order to enable diagnosis treatment and care on tuberculosis including multi-drug resistance (MDRTB) and extensively drug resistance tuberculosis (XDR-TB) by means of skill improvement training aimed at both general and specialized health workers through cooperation with non-governmental organizations (NGO) and inter-governmental partnership;

d. Promoting multi-sector discussion regarding the global crisis posed by the tuberculosis pandemic through the dissemination of important materials on efforts to fight the epidemic

e. Encouraging the incorporation of education on tuberculosis in health education classes on primary, secondary, and tertiary levels of education as well as the establishment of national-level campaigns against tuberculosis and discrimination to eradicate wrong stigma and misconceptions;

f. Introducing the decentralized production of generic, cheap, and effective drugs for tuberculosis to increase the accessibility of tuberculosis drugs for all and to lessen the dependency of high tuberculosis burden countries on patented drugs;

g. Introducing more efficient distribution system to increase access of TB drugs for at-risk vulnerable and/or inaccessible groups by, but not limited to, the means of minimizing and standardizing the shape of the drugs to increase its quantity in distribution;

Emphasizes the importance of comprehensive tuberculosis prevention programmes as an essential element in tailoring national, regional, and international actions and policies to tailor it to the local profile and the TB pandemic;

Endorses financial and technical assistance for the advancement of tools, technology, and medicine to combat tuberculosis by means of:

1. Increasing financial contributions made to date to the Global Fund to Fight AIDS, Tuberculosis and Malaria;

2. Empowering the work of Global Health Innovative Technology Fund (GHIT Fund) for the research and development of innovative tools and drugs to combat tuberculosis, including MDR-TB, XBR-TB and HIV/AIDS-related TB, as well as the development of accessible generic drugs and vaccines to improve the currently available tuberculosis vaccine (BCG) or to develop a new and more effective vaccine altogether, especially seeing that the currently available vaccine is not effective for children;

3. Strengthening the work of Stop TB Partnership Working Group and Global Alliance for TB Drug Development;

Strongly urges Members States of World Health Organization to deploy national-level laws, policies, and investments in order to eradicate the prevalence of tuberculosis in their states with focuses on research and development (R&D) as well as the production of accessible medicines and vaccines;

Strongly urges Member States to incorporate care services during and in the aftermath of the tuberculosis treatment, including but not limited to the monitoring of nutrition intake and sanitation;

Urges Member States to give a focus on the different needs and problems faced by women and children in accessing treatments for and information regarding tuberculosis by means of:

1. Encouraging the development of children-friendly drugs and vaccines as the current tuberculosis drugs require three to four different drugs for at least eighteen months of treatments with commendation of even more drugs and at least six months of injection that may have severe side effects for children;

2. Encouraging the development of pregnant women-friendly drugs which have no possible severe side effects that may affect the condition of the pregnant women and their fetus;

3. Integrating maternal, children, and women health services, HIV care, and tuberculosis care into a seamless package of national healthcare system;

Strengthens inter-United Nations bodies cooperation to eradicate tuberculosis, including cooperation with, but not limited to, the following UN bodies:

1. UN-WOMEN for grassroots education and campaigns regarding the rights of women for access to information, education, and medication with a focus on pregnant women, single mothers living below poverty line, and childrearing women;

2. UNICEF for the promotion of the incorporation of health education on national education system with an emphasize of education on awareness for tuberculosis;

3. World Food Programme (WFP) to strengthen its assistance for governments to integrate food and nutrition into health programmes and to build broad safety nets that protect livelihoods of persons with tuberculosis;

4. UNAIDS to strengthen its assistance for governments and regional bodies to promote anti-discrimination campaigns for persons with HIV/AIDS and TB as well as to promote joint-research to ensure accessible medicine and treatment for persons with HIV/AIDS and TB;

Strengthens support for treatment and care for tuberculosis during humanitarian emergencies and/or conflicts by means of:

- Short term: Encourage cooperation with national, regional, and international partners and stakeholders to establish accessible and safe supportive health care services to address tuberculosis and aid in its recovery during and immediately following the emergencies

- Long term: Establishment of sustainable and widely accessible community-based health system after the emergency

Expands the MDR-TB management to cover MDR-TB sufferers by the means of:1. Strengthening the framework of the Greenlight Committee Initiative partnered with STOP TB to

raise funds for establishing policies and principles from national- and government-supported agencies, regional and international organizations, non-governmental organizations, universities, research institutions, and other sources;

2. Ensuring transparency of distribution and management of health services and medicines by encouraging government-supported national monitoring and transparency assessment along with assessments sponsored by World Health Organization and non-governmental organizations;

Supports the eradication MDR-TB and XDR-TB altogether in the near future by the means of:1. Standardizing the Greenlight Committee Initiative (GCI) to support the expansion of the MDR-TB

treatments and care, to promote technical assistance to countries in the implementation and application of the standardized treatments, to monitor and evaluate GLC-approved programmes in ensuring their adherence to WHO and United Nations guidelines, and assist the development of policies on national and global level to control MDR-TB;

2. Calling upon Member States to offer their financial assistance for Global Health Innovative Technology Fund (GHIT Fund) for the development of cheaper and more effective drugs for MDR-TB and XDR-TB;

Encourages global and private-public partnership with an aim to eradicate tuberculosis in the near future by the means of:

1. PUBLIC-PRIVATE PARTNERSHIPa. Encouraging partnership between government and civil societies to establish

community-based, grassroots health care services and information systems, with a focus of civil societies for vulnerable groups, including people suffering from HIV/AIDS;

b. Encouraging partnership between government and non-governmental organizations to assist in the monitoring and assessment of the implementation of existing national and global policies, the distribution of drugs to unreachable areas, and knowledge transfer for local doctors and health service workers;

c. Encouraging partnership between government and multinational corporations with corporate social responsibility (CSR) programs, especially those in pharmaceutical and hospital industry, to assist in knowledge transfer and research and development of innovative tools and drugs to combat TB;

d. Encouraging partnership between government and media—including news outlets and social medias—to promote anti-discrimination campaign aimed at eliminating misconceptions and wrong stigma of the society in regards to tuberculosis;

2. GLOBAL PARTNERSHIPa. Encouraging bilateral agreements and the development of national laws to employ strict

screening policies for immigrants upon their arrival to resolve cross-border issues;b. Encouraging a universal standard for tuberculosis treatments and prevention

programmes;c. Implementing effective monitoring, evaluation, and impact measurement system for

existing initiatives, global or otherwise, including The Global Fund, DOTS and DOTS+, as well as the Stop TB Strategy, to ensure political commitment, effective drug supply and management system, as well as standardized treatment for tuberculosis patients;